JP2009504739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504739A5 JP2009504739A5 JP2008526995A JP2008526995A JP2009504739A5 JP 2009504739 A5 JP2009504739 A5 JP 2009504739A5 JP 2008526995 A JP2008526995 A JP 2008526995A JP 2008526995 A JP2008526995 A JP 2008526995A JP 2009504739 A5 JP2009504739 A5 JP 2009504739A5
- Authority
- JP
- Japan
- Prior art keywords
- naphthylsulfonyl
- indazol
- oxy
- ethyl
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cycloheteroalkyl Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000000547 substituted alkyl group Chemical group 0.000 claims 8
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 7
- 150000001412 amines Chemical class 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- NXQGEDVQXVTCDA-UHFFFAOYSA-N n,n-dimethyl-3-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]propan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCCN(C)C)=CC=CC2=C1 NXQGEDVQXVTCDA-UHFFFAOYSA-N 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- BDDKOKDVHRMTRN-QGZVFWFLSA-N (3r)-1-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)methyl]pyrrolidin-3-amine Chemical compound C1[C@H](N)CCN1CC1=CC=C(NN=C2S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C2=C1 BDDKOKDVHRMTRN-QGZVFWFLSA-N 0.000 claims 1
- MJFCJJYGVUCATE-KRWDZBQOSA-N (3s)-n-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)methyl]pyrrolidin-3-amine Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2CN[C@H]1CCNC1 MJFCJJYGVUCATE-KRWDZBQOSA-N 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- VQMIHBPSBVXFRK-UHFFFAOYSA-N 1-[(3-chlorophenyl)methyl]-3-naphthalen-1-ylsulfonyl-7-(2-piperidin-1-ylethoxy)indazole Chemical compound ClC1=CC=CC(CN2C3=C(OCCN4CCCCC4)C=CC=C3C(=N2)S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)=C1 VQMIHBPSBVXFRK-UHFFFAOYSA-N 0.000 claims 1
- HHMHKXHXVXCQLN-UHFFFAOYSA-N 1-[(3-chlorophenyl)methyl]-3-naphthalen-1-ylsulfonyl-7-(2-pyrrolidin-1-ylethoxy)indazole Chemical compound ClC1=CC=CC(CN2C3=C(OCCN4CCCC4)C=CC=C3C(=N2)S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)=C1 HHMHKXHXVXCQLN-UHFFFAOYSA-N 0.000 claims 1
- PSHLDNLWBBFDFD-UHFFFAOYSA-N 1-[(3-chlorophenyl)methyl]-3-naphthalen-1-ylsulfonyl-7-(3-pyrrolidin-1-ylpropoxy)indazole Chemical compound ClC1=CC=CC(CN2C3=C(OCCCN4CCCC4)C=CC=C3C(=N2)S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)=C1 PSHLDNLWBBFDFD-UHFFFAOYSA-N 0.000 claims 1
- AGNLTJIBWCCUJF-UHFFFAOYSA-N 1-[(3-chlorophenyl)methyl]-5-methoxy-3-naphthalen-1-ylsulfonyl-7-(2-piperidin-1-ylethoxy)indazole Chemical compound C=12N(CC=3C=C(Cl)C=CC=3)N=C(S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C2=CC(OC)=CC=1OCCN1CCCCC1 AGNLTJIBWCCUJF-UHFFFAOYSA-N 0.000 claims 1
- VGPQNSBBNUZHKK-UHFFFAOYSA-N 1-methyl-3-naphthalen-1-ylsulfonyl-5-(2-pyrrolidin-1-ylethoxy)indazole Chemical compound C=1C=C2N(C)N=C(S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C2=CC=1OCCN1CCCC1 VGPQNSBBNUZHKK-UHFFFAOYSA-N 0.000 claims 1
- KLFVGUJOLHGRGQ-UHFFFAOYSA-N 1-methyl-3-naphthalen-1-ylsulfonyl-7-(2-piperidin-1-ylethoxy)indazole Chemical compound C=12N(C)N=C(S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C2=CC=CC=1OCCN1CCCCC1 KLFVGUJOLHGRGQ-UHFFFAOYSA-N 0.000 claims 1
- VAXXDAHKMQRFOK-UHFFFAOYSA-N 1-methyl-3-naphthalen-1-ylsulfonyl-7-(2-pyrrolidin-1-ylethoxy)indazole Chemical compound C=12N(C)N=C(S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C2=CC=CC=1OCCN1CCCC1 VAXXDAHKMQRFOK-UHFFFAOYSA-N 0.000 claims 1
- JOKVCTPPRWTZIZ-UHFFFAOYSA-N 2-(1-benzyl-3-naphthalen-1-ylsulfonylindazol-5-yl)oxy-n,n-dimethylethanamine Chemical compound N1=C(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C2=CC(OCCN(C)C)=CC=C2N1CC1=CC=CC=C1 JOKVCTPPRWTZIZ-UHFFFAOYSA-N 0.000 claims 1
- CIOWMQRPUTVJAD-UHFFFAOYSA-N 2-(1-benzyl-3-naphthalen-1-ylsulfonylindazol-5-yl)oxy-n-ethylethanamine Chemical compound N1=C(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C2=CC(OCCNCC)=CC=C2N1CC1=CC=CC=C1 CIOWMQRPUTVJAD-UHFFFAOYSA-N 0.000 claims 1
- YUJDLCUEQASUOZ-UHFFFAOYSA-N 2-(1-benzyl-3-naphthalen-1-ylsulfonylindazol-5-yl)oxy-n-methylethanamine Chemical compound N1=C(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C2=CC(OCCNC)=CC=C2N1CC1=CC=CC=C1 YUJDLCUEQASUOZ-UHFFFAOYSA-N 0.000 claims 1
- IPXNIBQIWMLOIQ-UHFFFAOYSA-N 2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-4-yl)oxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC=4C=CC=C(C3=4)OCCN)=CC=CC2=C1 IPXNIBQIWMLOIQ-UHFFFAOYSA-N 0.000 claims 1
- OIWRJIJOAUHKGP-UHFFFAOYSA-N 2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-6-yl)oxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C4=CC=C(C=C4NN=3)OCCN)=CC=CC2=C1 OIWRJIJOAUHKGP-UHFFFAOYSA-N 0.000 claims 1
- HMYUFCVGTBDGEL-UHFFFAOYSA-N 2-[(5-fluoro-3-naphthalen-1-ylsulfonyl-2h-indazol-7-yl)oxy]-n,n-dimethylethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C=4C=C(F)C=C(C=4NN=3)OCCN(C)C)=CC=CC2=C1 HMYUFCVGTBDGEL-UHFFFAOYSA-N 0.000 claims 1
- MKDGUGOLAULVEG-UHFFFAOYSA-N 2-[(5-fluoro-3-naphthalen-1-ylsulfonyl-2h-indazol-7-yl)oxy]-n-methylethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C=4C=C(F)C=C(C=4NN=3)OCCNC)=CC=CC2=C1 MKDGUGOLAULVEG-UHFFFAOYSA-N 0.000 claims 1
- PRINITFWFJYFNK-UHFFFAOYSA-N 2-[(5-methoxy-3-naphthalen-1-ylsulfonyl-2h-indazol-7-yl)oxy]-n,n-dimethylethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=C(OCCN(C)C)C=C(C=C43)OC)=CC=CC2=C1 PRINITFWFJYFNK-UHFFFAOYSA-N 0.000 claims 1
- KELNGYBJXUYADG-UHFFFAOYSA-N 2-[(5-methoxy-3-naphthalen-1-ylsulfonyl-2h-indazol-7-yl)oxy]-n-methylethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C=4C=C(OC)C=C(C=4NN=3)OCCNC)=CC=CC2=C1 KELNGYBJXUYADG-UHFFFAOYSA-N 0.000 claims 1
- HVVHTDCEKSEIDP-UHFFFAOYSA-N 2-[1-[(3-chlorophenyl)methyl]-3-naphthalen-1-ylsulfonylindazol-5-yl]oxy-n,n-dimethylethanamine Chemical compound N1=C(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C2=CC(OCCN(C)C)=CC=C2N1CC1=CC=CC(Cl)=C1 HVVHTDCEKSEIDP-UHFFFAOYSA-N 0.000 claims 1
- BCZIOHHWLJAHLB-UHFFFAOYSA-N 2-[1-[(3-chlorophenyl)methyl]-3-naphthalen-1-ylsulfonylindazol-5-yl]oxy-n-ethylethanamine Chemical compound N1=C(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C2=CC(OCCNCC)=CC=C2N1CC1=CC=CC(Cl)=C1 BCZIOHHWLJAHLB-UHFFFAOYSA-N 0.000 claims 1
- PUECJZJYCKEXGK-UHFFFAOYSA-N 2-[1-[(3-chlorophenyl)methyl]-3-naphthalen-1-ylsulfonylindazol-7-yl]oxy-n-ethylethanamine Chemical compound C1=2C(OCCNCC)=CC=CC=2C(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)=NN1CC1=CC=CC(Cl)=C1 PUECJZJYCKEXGK-UHFFFAOYSA-N 0.000 claims 1
- GISNOEZWSXUMJI-UHFFFAOYSA-N 2-[1-[(3-chlorophenyl)methyl]-3-naphthalen-1-ylsulfonylindazol-7-yl]oxy-n-methylethanamine Chemical compound C1=2C(OCCNC)=CC=CC=2C(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)=NN1CC1=CC=CC(Cl)=C1 GISNOEZWSXUMJI-UHFFFAOYSA-N 0.000 claims 1
- GLMCMWNITAAMIM-UHFFFAOYSA-N 2-[1-[(3-chlorophenyl)methyl]-5-fluoro-3-naphthalen-1-ylsulfonylindazol-7-yl]oxy-n,n-dimethylethanamine Chemical compound C1=2C(OCCN(C)C)=CC(F)=CC=2C(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)=NN1CC1=CC=CC(Cl)=C1 GLMCMWNITAAMIM-UHFFFAOYSA-N 0.000 claims 1
- JURYICOBMPOCAG-UHFFFAOYSA-N 2-[3-(benzenesulfonyl)-1-[(3-chlorophenyl)methyl]indazol-7-yl]oxy-n-ethylethanamine Chemical compound C1=2C(OCCNCC)=CC=CC=2C(S(=O)(=O)C=2C=CC=CC=2)=NN1CC1=CC=CC(Cl)=C1 JURYICOBMPOCAG-UHFFFAOYSA-N 0.000 claims 1
- URGWMZAHFHDSAB-UHFFFAOYSA-N 2-[3-(benzenesulfonyl)-1-[(3-chlorophenyl)methyl]indazol-7-yl]oxy-n-methylethanamine Chemical compound C1=2C(OCCNC)=CC=CC=2C(S(=O)(=O)C=2C=CC=CC=2)=NN1CC1=CC=CC(Cl)=C1 URGWMZAHFHDSAB-UHFFFAOYSA-N 0.000 claims 1
- LJNYDPDAMOHONR-UHFFFAOYSA-N 2-[3-(benzenesulfonyl)-1-methylindazol-7-yl]oxy-n-methylethanamine Chemical compound N=1N(C)C=2C(OCCNC)=CC=CC=2C=1S(=O)(=O)C1=CC=CC=C1 LJNYDPDAMOHONR-UHFFFAOYSA-N 0.000 claims 1
- FFXYPUZNRSHAQG-UHFFFAOYSA-N 2-[3-(benzenesulfonyl)-2h-indazol-5-yl]-n-methylethanamine Chemical compound C12=CC(CCNC)=CC=C2NN=C1S(=O)(=O)C1=CC=CC=C1 FFXYPUZNRSHAQG-UHFFFAOYSA-N 0.000 claims 1
- HDXBREGAPLXGIS-UHFFFAOYSA-N 2-[[3-(benzenesulfonyl)-2h-indazol-5-yl]oxy]-n,n-dimethylethanamine Chemical compound C12=CC(OCCN(C)C)=CC=C2NN=C1S(=O)(=O)C1=CC=CC=C1 HDXBREGAPLXGIS-UHFFFAOYSA-N 0.000 claims 1
- NTWIXXNPWJCUKO-UHFFFAOYSA-N 2-[[3-(benzenesulfonyl)-2h-indazol-5-yl]oxy]-n-ethylethanamine Chemical compound C12=CC(OCCNCC)=CC=C2NN=C1S(=O)(=O)C1=CC=CC=C1 NTWIXXNPWJCUKO-UHFFFAOYSA-N 0.000 claims 1
- YRZHGGDYKODNJU-UHFFFAOYSA-N 2-[[3-(benzenesulfonyl)-2h-indazol-5-yl]oxy]-n-methylethanamine Chemical compound C12=CC(OCCNC)=CC=C2NN=C1S(=O)(=O)C1=CC=CC=C1 YRZHGGDYKODNJU-UHFFFAOYSA-N 0.000 claims 1
- WHXDIHVWZAGDKC-UHFFFAOYSA-N 2-[[3-(benzenesulfonyl)-2h-indazol-7-yl]oxy]-n,n-diethylethanamine Chemical compound N=1NC=2C(OCCN(CC)CC)=CC=CC=2C=1S(=O)(=O)C1=CC=CC=C1 WHXDIHVWZAGDKC-UHFFFAOYSA-N 0.000 claims 1
- AORXKAAXUHVTJR-UHFFFAOYSA-N 2-[[3-(benzenesulfonyl)-2h-indazol-7-yl]oxy]-n-ethylethanamine Chemical compound N=1NC=2C(OCCNCC)=CC=CC=2C=1S(=O)(=O)C1=CC=CC=C1 AORXKAAXUHVTJR-UHFFFAOYSA-N 0.000 claims 1
- DLEJEOYCUICQJI-UHFFFAOYSA-N 2-[[3-(benzenesulfonyl)-2h-indazol-7-yl]oxy]-n-methylethanamine Chemical compound N=1NC=2C(OCCNC)=CC=CC=2C=1S(=O)(=O)C1=CC=CC=C1 DLEJEOYCUICQJI-UHFFFAOYSA-N 0.000 claims 1
- MFTFRMAELXKCND-UHFFFAOYSA-N 2-[[3-(benzenesulfonyl)-2h-indazol-7-yl]oxy]ethanamine Chemical compound N=1NC=2C(OCCN)=CC=CC=2C=1S(=O)(=O)C1=CC=CC=C1 MFTFRMAELXKCND-UHFFFAOYSA-N 0.000 claims 1
- PVHHQFSLPRWAAC-UHFFFAOYSA-N 2-[[3-(benzenesulfonyl)-5-fluoro-2h-indazol-7-yl]oxy]ethanamine Chemical compound N=1NC=2C(OCCN)=CC(F)=CC=2C=1S(=O)(=O)C1=CC=CC=C1 PVHHQFSLPRWAAC-UHFFFAOYSA-N 0.000 claims 1
- FPJHIKFHOMVDHT-UHFFFAOYSA-N 3-(2-aminoethyl)-1-(2,5-dimethoxyphenyl)sulfonylimidazo[4,5-b]pyridin-2-one Chemical compound COC1=CC=C(OC)C(S(=O)(=O)N2C(N(CCN)C3=NC=CC=C32)=O)=C1 FPJHIKFHOMVDHT-UHFFFAOYSA-N 0.000 claims 1
- JJOUYXALLGKCDX-UHFFFAOYSA-N 3-(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)-n-propan-2-ylpropan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)CCCNC(C)C)=CC=CC2=C1 JJOUYXALLGKCDX-UHFFFAOYSA-N 0.000 claims 1
- ANVYWTVXAOYYQR-UHFFFAOYSA-N 3-(benzenesulfonyl)-1-[(3-chlorophenyl)methyl]-7-(2-pyrrolidin-1-ylethoxy)indazole Chemical compound ClC1=CC=CC(CN2C3=C(OCCN4CCCC4)C=CC=C3C(=N2)S(=O)(=O)C=2C=CC=CC=2)=C1 ANVYWTVXAOYYQR-UHFFFAOYSA-N 0.000 claims 1
- UHFMTHFRISAZAP-UHFFFAOYSA-N 3-(benzenesulfonyl)-1-methyl-7-(2-pyrrolidin-1-ylethoxy)indazole Chemical compound C=12N(C)N=C(S(=O)(=O)C=3C=CC=CC=3)C2=CC=CC=1OCCN1CCCC1 UHFMTHFRISAZAP-UHFFFAOYSA-N 0.000 claims 1
- LDXXPFIHTIGYPU-UHFFFAOYSA-N 3-(benzenesulfonyl)-5-(2-piperidin-1-ylethoxy)-2h-indazole Chemical compound C=1C=CC=CC=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCN1CCCCC1 LDXXPFIHTIGYPU-UHFFFAOYSA-N 0.000 claims 1
- UGZYQDUVEDXGHV-UHFFFAOYSA-N 3-(benzenesulfonyl)-5-(2-pyrrolidin-1-ylethoxy)-2h-indazole Chemical compound C=1C=CC=CC=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCN1CCCC1 UGZYQDUVEDXGHV-UHFFFAOYSA-N 0.000 claims 1
- WIYJNVVWQUAPGH-UHFFFAOYSA-N 3-(benzenesulfonyl)-7-(2-piperidin-1-ylethoxy)-2h-indazole Chemical compound C=1C=CC=CC=1S(=O)(=O)C(C1=CC=C2)=NNC1=C2OCCN1CCCCC1 WIYJNVVWQUAPGH-UHFFFAOYSA-N 0.000 claims 1
- OZNZMUDIXBKUNZ-UHFFFAOYSA-N 3-(benzenesulfonyl)-7-(2-pyrrolidin-1-ylethoxy)-2h-indazole Chemical compound C=1C=CC=CC=1S(=O)(=O)C(C1=CC=C2)=NNC1=C2OCCN1CCCC1 OZNZMUDIXBKUNZ-UHFFFAOYSA-N 0.000 claims 1
- HTQJWNJUJIRONG-UHFFFAOYSA-N 3-(ethylamino)-N-(3-naphthalen-1-ylsulfonyl-2H-indazol-7-yl)pentanamide Chemical compound C(C)C(NCC)CC(=O)NC=1C=CC=C2C(=NNC=12)S(=O)(=O)C1=CC=CC2=CC=CC=C12 HTQJWNJUJIRONG-UHFFFAOYSA-N 0.000 claims 1
- PTCSHLCQBWNEIT-UHFFFAOYSA-N 3-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]-n-propan-2-ylpropan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCCNC(C)C)=CC=CC2=C1 PTCSHLCQBWNEIT-UHFFFAOYSA-N 0.000 claims 1
- KAWWRYOKLNMCFP-UHFFFAOYSA-N 3-[1-[(3-chlorophenyl)methyl]-3-naphthalen-1-ylsulfonylindazol-7-yl]oxy-n,n-diethylpropan-1-amine Chemical compound C1=2C(OCCCN(CC)CC)=CC=CC=2C(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)=NN1CC1=CC=CC(Cl)=C1 KAWWRYOKLNMCFP-UHFFFAOYSA-N 0.000 claims 1
- LLZGCYHPURCHJM-UHFFFAOYSA-N 3-amino-n-(3-naphthalen-1-ylsulfonyl-2h-indazol-6-yl)propanamide Chemical compound C1=CC=C2C(S(=O)(=O)C=3C4=CC=C(C=C4NN=3)NC(=O)CCN)=CC=CC2=C1 LLZGCYHPURCHJM-UHFFFAOYSA-N 0.000 claims 1
- OWHIEVZLTSBQQK-UHFFFAOYSA-N 3-amino-n-(3-naphthalen-1-ylsulfonyl-2h-indazol-7-yl)propanamide Chemical compound C1=CC=C2C(S(=O)(=O)C=3C=4C=CC=C(C=4NN=3)NC(=O)CCN)=CC=CC2=C1 OWHIEVZLTSBQQK-UHFFFAOYSA-N 0.000 claims 1
- HEZLMJIASCHADF-UHFFFAOYSA-N 3-naphthalen-1-ylsulfonyl-4-(2-piperidin-1-ylethoxy)-2h-indazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C=12)=NNC2=CC=CC=1OCCN1CCCCC1 HEZLMJIASCHADF-UHFFFAOYSA-N 0.000 claims 1
- WQVVPQOPYLVTPT-UHFFFAOYSA-N 3-naphthalen-1-ylsulfonyl-4-(2-pyrrolidin-1-ylethoxy)-2h-indazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C=12)=NNC2=CC=CC=1OCCN1CCCC1 WQVVPQOPYLVTPT-UHFFFAOYSA-N 0.000 claims 1
- DUCYBBPHJUIGNA-UHFFFAOYSA-N 3-naphthalen-1-ylsulfonyl-5-(2-piperidin-1-ylethoxy)-2h-indazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCN1CCCCC1 DUCYBBPHJUIGNA-UHFFFAOYSA-N 0.000 claims 1
- BXFCAALYQGLMJW-UHFFFAOYSA-N 3-naphthalen-1-ylsulfonyl-5-(2-pyrrolidin-1-ylethoxy)-2h-indazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCN1CCCC1 BXFCAALYQGLMJW-UHFFFAOYSA-N 0.000 claims 1
- AQYVCBJKCBJVRX-UHFFFAOYSA-N 3-naphthalen-1-ylsulfonyl-5-(3-piperidin-1-ylpropoxy)-2h-indazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCCN1CCCCC1 AQYVCBJKCBJVRX-UHFFFAOYSA-N 0.000 claims 1
- SDCUZMUHLPBVER-UHFFFAOYSA-N 3-naphthalen-1-ylsulfonyl-5-(3-pyrrolidin-1-ylpropoxy)-2h-indazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCCN1CCCC1 SDCUZMUHLPBVER-UHFFFAOYSA-N 0.000 claims 1
- MUWNVAFGUSCAGK-UHFFFAOYSA-N 3-naphthalen-1-ylsulfonyl-5-(3-pyrrolidin-1-ylpropyl)-2h-indazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2CCCN1CCCC1 MUWNVAFGUSCAGK-UHFFFAOYSA-N 0.000 claims 1
- QJHZJEQBNYBRCI-UHFFFAOYSA-N 3-naphthalen-1-ylsulfonyl-5-(4-piperidin-1-ylbutoxy)-2h-indazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCCCN1CCCCC1 QJHZJEQBNYBRCI-UHFFFAOYSA-N 0.000 claims 1
- FEPZFVMKSRZBPE-UHFFFAOYSA-N 3-naphthalen-1-ylsulfonyl-5-(4-pyrrolidin-1-ylbutoxy)-2h-indazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCCCN1CCCC1 FEPZFVMKSRZBPE-UHFFFAOYSA-N 0.000 claims 1
- JSVSTRRSIPLHHJ-UHFFFAOYSA-N 3-naphthalen-1-ylsulfonyl-5-(4-pyrrolidin-1-ylbutyl)-2h-indazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2CCCCN1CCCC1 JSVSTRRSIPLHHJ-UHFFFAOYSA-N 0.000 claims 1
- XUYRYAFLMVXIKP-UHFFFAOYSA-N 3-naphthalen-1-ylsulfonyl-5-(piperazin-1-ylmethyl)-2h-indazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2CN1CCNCC1 XUYRYAFLMVXIKP-UHFFFAOYSA-N 0.000 claims 1
- BESVINGVIMNVTM-UHFFFAOYSA-N 3-naphthalen-1-ylsulfonyl-7-(2-piperidin-1-ylethoxy)-2h-indazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=CC=C2)=NNC1=C2OCCN1CCCCC1 BESVINGVIMNVTM-UHFFFAOYSA-N 0.000 claims 1
- AWZSBFZVBKOHCU-UHFFFAOYSA-N 3-naphthalen-1-ylsulfonyl-7-(2-pyrrolidin-1-ylethoxy)-2h-indazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=CC=C2)=NNC1=C2OCCN1CCCC1 AWZSBFZVBKOHCU-UHFFFAOYSA-N 0.000 claims 1
- QSLGLGHRVKEICG-UHFFFAOYSA-N 4-(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)-n-propan-2-ylbutan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)CCCCNC(C)C)=CC=CC2=C1 QSLGLGHRVKEICG-UHFFFAOYSA-N 0.000 claims 1
- CJAMWNIUXVSUAX-UHFFFAOYSA-N 4-[2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]ethyl]morpholine Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCN1CCOCC1 CJAMWNIUXVSUAX-UHFFFAOYSA-N 0.000 claims 1
- SMYKNLXIBOTGRX-UHFFFAOYSA-N 4-[3-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]propyl]morpholine Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCCN1CCOCC1 SMYKNLXIBOTGRX-UHFFFAOYSA-N 0.000 claims 1
- 108091005435 5-HT6 receptors Proteins 0.000 claims 1
- QGFXCRXBCKGGPI-UHFFFAOYSA-N 5-[(3,5-dimethylpiperazin-1-yl)methyl]-3-naphthalen-1-ylsulfonyl-2h-indazole Chemical compound C1C(C)NC(C)CN1CC1=CC=C(NN=C2S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C2=C1 QGFXCRXBCKGGPI-UHFFFAOYSA-N 0.000 claims 1
- ZINGRIDQXCYQHG-UHFFFAOYSA-N 5-[(3-methylpiperazin-1-yl)methyl]-3-naphthalen-1-ylsulfonyl-2h-indazole Chemical compound C1CNC(C)CN1CC1=CC=C(NN=C2S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C2=C1 ZINGRIDQXCYQHG-UHFFFAOYSA-N 0.000 claims 1
- BVGUWXHNURCART-UHFFFAOYSA-N 5-[(4-methylpiperazin-1-yl)methyl]-3-naphthalen-1-ylsulfonyl-2h-indazole Chemical compound C1CN(C)CCN1CC1=CC=C(NN=C2S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C2=C1 BVGUWXHNURCART-UHFFFAOYSA-N 0.000 claims 1
- BRZICYPAZGCYJB-UHFFFAOYSA-N 5-[1-(4-methylpiperazin-1-yl)ethyl]-3-naphthalen-1-ylsulfonyl-2h-indazole Chemical compound C=1C=C2NN=C(S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C2=CC=1C(C)N1CCN(C)CC1 BRZICYPAZGCYJB-UHFFFAOYSA-N 0.000 claims 1
- ZINGRIDQXCYQHG-MRXNPFEDSA-N 5-[[(3r)-3-methylpiperazin-1-yl]methyl]-3-naphthalen-1-ylsulfonyl-2h-indazole Chemical compound C1CN[C@H](C)CN1CC1=CC=C(NN=C2S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C2=C1 ZINGRIDQXCYQHG-MRXNPFEDSA-N 0.000 claims 1
- RRVKJPOYMLUVPI-UHFFFAOYSA-N 5-fluoro-3-naphthalen-1-ylsulfonyl-7-(2-piperidin-1-ylethoxy)-2h-indazole Chemical compound C=12NN=C(S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C2=CC(F)=CC=1OCCN1CCCCC1 RRVKJPOYMLUVPI-UHFFFAOYSA-N 0.000 claims 1
- GCPXIXQOCOSHQJ-UHFFFAOYSA-N 5-fluoro-3-naphthalen-1-ylsulfonyl-7-(2-pyrrolidin-1-ylethoxy)-2h-indazole Chemical compound C=12NN=C(S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C2=CC(F)=CC=1OCCN1CCCC1 GCPXIXQOCOSHQJ-UHFFFAOYSA-N 0.000 claims 1
- MDGWPYQLNCCSTA-UHFFFAOYSA-N 5-methoxy-3-naphthalen-1-ylsulfonyl-7-(2-piperidin-1-ylethoxy)-2h-indazole Chemical compound C=12NN=C(S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C2=CC(OC)=CC=1OCCN1CCCCC1 MDGWPYQLNCCSTA-UHFFFAOYSA-N 0.000 claims 1
- BULLQEWAUCBKMX-UHFFFAOYSA-N 5-methoxy-3-naphthalen-1-ylsulfonyl-7-(2-pyrrolidin-1-ylethoxy)-2h-indazole Chemical compound C=12NN=C(S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C2=CC(OC)=CC=1OCCN1CCCC1 BULLQEWAUCBKMX-UHFFFAOYSA-N 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- IXSMRKQJNLSAEU-UHFFFAOYSA-N N,N-dimethyl-4-[(3-naphthalen-1-ylsulfonyl-2H-indazol-5-yl)oxy]butan-1-amine N-methyl-4-[(3-naphthalen-1-ylsulfonyl-2H-indazol-5-yl)oxy]butan-1-amine Chemical compound CNCCCCOc1ccc2[nH]nc(c2c1)S(=O)(=O)c1cccc2ccccc12.CN(C)CCCCOc1ccc2[nH]nc(c2c1)S(=O)(=O)c1cccc2ccccc12 IXSMRKQJNLSAEU-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- ULEAQRIQMIQDPJ-UHFFFAOYSA-N butane-1,2-diamine Chemical compound CCC(N)CN ULEAQRIQMIQDPJ-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- RQOKMHCTFHXXMM-UHFFFAOYSA-N n'-(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)ethane-1,2-diamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)NCCN)=CC=CC2=C1 RQOKMHCTFHXXMM-UHFFFAOYSA-N 0.000 claims 1
- QXPWRAXEWDBKHX-UHFFFAOYSA-N n'-(3-naphthalen-1-ylsulfonyl-2h-indazol-6-yl)ethane-1,2-diamine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C4=CC=C(C=C4NN=3)NCCN)=CC=CC2=C1 QXPWRAXEWDBKHX-UHFFFAOYSA-N 0.000 claims 1
- QYCVGIKLACULSQ-UHFFFAOYSA-N n'-(3-naphthalen-1-ylsulfonyl-2h-indazol-7-yl)ethane-1,2-diamine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C=4C=CC=C(C=4NN=3)NCCN)=CC=CC2=C1 QYCVGIKLACULSQ-UHFFFAOYSA-N 0.000 claims 1
- FNEPLPAYLVDBNM-UHFFFAOYSA-N n'-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)methyl]ethane-1,2-diamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)CNCCN)=CC=CC2=C1 FNEPLPAYLVDBNM-UHFFFAOYSA-N 0.000 claims 1
- YVZYTWQZGQNPAY-UHFFFAOYSA-N n,n,n'-trimethyl-n'-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)methyl]ethane-1,2-diamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)CN(C)CCN(C)C)=CC=CC2=C1 YVZYTWQZGQNPAY-UHFFFAOYSA-N 0.000 claims 1
- OIGKUILSSYMBFJ-UHFFFAOYSA-N n,n-diethyl-2-(1-methyl-3-naphthalen-1-ylsulfonylindazol-5-yl)oxyethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NN(C)C4=CC=C(C=C43)OCCN(CC)CC)=CC=CC2=C1 OIGKUILSSYMBFJ-UHFFFAOYSA-N 0.000 claims 1
- JEYSUQQUTIWEEF-UHFFFAOYSA-N n,n-diethyl-2-(1-methyl-3-naphthalen-1-ylsulfonylindazol-7-yl)oxyethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C=4C=CC=C(C=4N(C)N=3)OCCN(CC)CC)=CC=CC2=C1 JEYSUQQUTIWEEF-UHFFFAOYSA-N 0.000 claims 1
- DMCNDPIVSZOUSA-UHFFFAOYSA-N n,n-diethyl-2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCN(CC)CC)=CC=CC2=C1 DMCNDPIVSZOUSA-UHFFFAOYSA-N 0.000 claims 1
- FLRJCYWJZNJPAJ-UHFFFAOYSA-N n,n-diethyl-2-[(5-fluoro-3-naphthalen-1-ylsulfonyl-2h-indazol-7-yl)oxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C=4C=C(F)C=C(C=4NN=3)OCCN(CC)CC)=CC=CC2=C1 FLRJCYWJZNJPAJ-UHFFFAOYSA-N 0.000 claims 1
- FSUSRKMBYMEREP-UHFFFAOYSA-N n,n-diethyl-3-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]propan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCCN(CC)CC)=CC=CC2=C1 FSUSRKMBYMEREP-UHFFFAOYSA-N 0.000 claims 1
- BGRBBWMOYJRGSK-UHFFFAOYSA-N n,n-diethyl-3-[(3-naphthalen-1-ylsulfonyl-2h-indazol-7-yl)oxy]propan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C=4C=CC=C(C=4NN=3)OCCCN(CC)CC)=CC=CC2=C1 BGRBBWMOYJRGSK-UHFFFAOYSA-N 0.000 claims 1
- KMVSONDYAPBQHT-UHFFFAOYSA-N n,n-diethyl-4-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]butan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCCCN(CC)CC)=CC=CC2=C1 KMVSONDYAPBQHT-UHFFFAOYSA-N 0.000 claims 1
- JZJVVXUVKTVXSC-UHFFFAOYSA-N n,n-dimethyl-2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-4-yl)oxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC=4C=CC=C(C3=4)OCCN(C)C)=CC=CC2=C1 JZJVVXUVKTVXSC-UHFFFAOYSA-N 0.000 claims 1
- GIFIQASYBXMCJY-UHFFFAOYSA-N n,n-dimethyl-2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)methoxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)COCCN(C)C)=CC=CC2=C1 GIFIQASYBXMCJY-UHFFFAOYSA-N 0.000 claims 1
- FZIDAMYBULCBST-UHFFFAOYSA-N n,n-dimethyl-2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCN(C)C)=CC=CC2=C1 FZIDAMYBULCBST-UHFFFAOYSA-N 0.000 claims 1
- KIIXTMKHCQBIED-UHFFFAOYSA-N n,n-dimethyl-2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-7-yl)oxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C=4C=CC=C(C=4NN=3)OCCN(C)C)=CC=CC2=C1 KIIXTMKHCQBIED-UHFFFAOYSA-N 0.000 claims 1
- VCOPJXGPLYGQDT-UHFFFAOYSA-N n,n-dimethyl-3-(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)propan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)CCCN(C)C)=CC=CC2=C1 VCOPJXGPLYGQDT-UHFFFAOYSA-N 0.000 claims 1
- GQCRISDKILEPEY-UHFFFAOYSA-N n,n-dimethyl-4-(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)butan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)CCCCN(C)C)=CC=CC2=C1 GQCRISDKILEPEY-UHFFFAOYSA-N 0.000 claims 1
- NAAMMAQETSMMJD-UHFFFAOYSA-N n-(3-naphthalen-1-ylsulfonyl-2h-indazol-6-yl)-3-piperidin-1-ylpropanamide Chemical compound C=1C=C2C(S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)=NNC2=CC=1NC(=O)CCN1CCCCC1 NAAMMAQETSMMJD-UHFFFAOYSA-N 0.000 claims 1
- LKIQFTRZQPOTFJ-UHFFFAOYSA-N n-(3-naphthalen-1-ylsulfonyl-2h-indazol-7-yl)-3-piperidin-1-ylpropanamide Chemical compound C=1C=CC=2C(S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)=NNC=2C=1NC(=O)CCN1CCCCC1 LKIQFTRZQPOTFJ-UHFFFAOYSA-N 0.000 claims 1
- VCHCBGQDIOIUSD-UHFFFAOYSA-N n-[2-(1-methyl-3-naphthalen-1-ylsulfonylindazol-5-yl)oxyethyl]propan-2-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NN(C)C4=CC=C(C=C43)OCCNC(C)C)=CC=CC2=C1 VCHCBGQDIOIUSD-UHFFFAOYSA-N 0.000 claims 1
- DJYOQELQMOJWCC-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-3-naphthalen-1-ylsulfonyl-2h-indazole-5-carboxamide Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)C(=O)NCCN(C)C)=CC=CC2=C1 DJYOQELQMOJWCC-UHFFFAOYSA-N 0.000 claims 1
- VUKPWKNVDTZIIO-UHFFFAOYSA-N n-[2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]ethyl]butan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCNCCCC)=CC=CC2=C1 VUKPWKNVDTZIIO-UHFFFAOYSA-N 0.000 claims 1
- YAYVSICZNRZOGT-UHFFFAOYSA-N n-[2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]ethyl]cyclopentanamine Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCNC1CCCC1 YAYVSICZNRZOGT-UHFFFAOYSA-N 0.000 claims 1
- MDTWXGWSXAWFTR-UHFFFAOYSA-N n-[2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]ethyl]cyclopropanamine Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCNC1CC1 MDTWXGWSXAWFTR-UHFFFAOYSA-N 0.000 claims 1
- ISLLLFJSCFDYNX-UHFFFAOYSA-N n-[2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]ethyl]propan-2-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCNC(C)C)=CC=CC2=C1 ISLLLFJSCFDYNX-UHFFFAOYSA-N 0.000 claims 1
- MQWHAZNMNZNWCX-UHFFFAOYSA-N n-[2-[3-(benzenesulfonyl)-2h-indazol-7-yl]ethyl]cyclopropanamine Chemical compound C=1C=CC=CC=1S(=O)(=O)C(C1=CC=C2)=NNC1=C2CCNC1CC1 MQWHAZNMNZNWCX-UHFFFAOYSA-N 0.000 claims 1
- AAXRJUUYWCWJBW-UHFFFAOYSA-N n-[2-[[3-(benzenesulfonyl)-2h-indazol-5-yl]oxy]ethyl]cyclopentanamine Chemical compound C=1C=CC=CC=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCNC1CCCC1 AAXRJUUYWCWJBW-UHFFFAOYSA-N 0.000 claims 1
- FNRWMGYHMJLWDN-UHFFFAOYSA-N n-[2-[[3-(benzenesulfonyl)-2h-indazol-5-yl]oxy]ethyl]propan-2-amine Chemical compound C12=CC(OCCNC(C)C)=CC=C2NN=C1S(=O)(=O)C1=CC=CC=C1 FNRWMGYHMJLWDN-UHFFFAOYSA-N 0.000 claims 1
- RHOSAQSWTNFUCW-UHFFFAOYSA-N n-[2-[[3-(benzenesulfonyl)-2h-indazol-7-yl]oxy]ethyl]butan-1-amine Chemical compound N=1NC=2C(OCCNCCCC)=CC=CC=2C=1S(=O)(=O)C1=CC=CC=C1 RHOSAQSWTNFUCW-UHFFFAOYSA-N 0.000 claims 1
- LKWUURPREMRAAG-UHFFFAOYSA-N n-[3-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]propyl]butan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCCNCCCC)=CC=CC2=C1 LKWUURPREMRAAG-UHFFFAOYSA-N 0.000 claims 1
- LQTIUQBMJBAWMD-UHFFFAOYSA-N n-[3-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]propyl]cyclopentanamine Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCCNC1CCCC1 LQTIUQBMJBAWMD-UHFFFAOYSA-N 0.000 claims 1
- ROYVCTNFSAPNLB-UHFFFAOYSA-N n-[3-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]propyl]cyclopropanamine Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2OCCCNC1CC1 ROYVCTNFSAPNLB-UHFFFAOYSA-N 0.000 claims 1
- BOMDVAWDCALISF-UHFFFAOYSA-N n-[3-[3-(benzenesulfonyl)-2h-indazol-5-yl]propyl]cyclopropanamine Chemical compound C=1C=CC=CC=1S(=O)(=O)C(C1=C2)=NNC1=CC=C2CCCNC1CC1 BOMDVAWDCALISF-UHFFFAOYSA-N 0.000 claims 1
- LJXLTOUCKSNHLN-UHFFFAOYSA-N n-ethyl-2-(1-methyl-3-naphthalen-1-ylsulfonylindazol-5-yl)oxyethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NN(C)C4=CC=C(C=C43)OCCNCC)=CC=CC2=C1 LJXLTOUCKSNHLN-UHFFFAOYSA-N 0.000 claims 1
- AIBJSOCDGUOKCX-UHFFFAOYSA-N n-ethyl-2-(1-methyl-3-naphthalen-1-ylsulfonylindazol-7-yl)oxyethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C=4C=CC=C(C=4N(C)N=3)OCCNCC)=CC=CC2=C1 AIBJSOCDGUOKCX-UHFFFAOYSA-N 0.000 claims 1
- NKQVYPRRVFKJKV-UHFFFAOYSA-N n-ethyl-2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCNCC)=CC=CC2=C1 NKQVYPRRVFKJKV-UHFFFAOYSA-N 0.000 claims 1
- XUUXCWWCIUMXON-UHFFFAOYSA-N n-ethyl-2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-7-yl)oxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C=4C=CC=C(C=4NN=3)OCCNCC)=CC=CC2=C1 XUUXCWWCIUMXON-UHFFFAOYSA-N 0.000 claims 1
- VMZSUVXRPPNISM-UHFFFAOYSA-N n-ethyl-2-[(5-fluoro-3-naphthalen-1-ylsulfonyl-2h-indazol-7-yl)oxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C=4C=C(F)C=C(C=4NN=3)OCCNCC)=CC=CC2=C1 VMZSUVXRPPNISM-UHFFFAOYSA-N 0.000 claims 1
- UBZDXQGFVPTXDZ-UHFFFAOYSA-N n-ethyl-3-(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)propan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)CCCNCC)=CC=CC2=C1 UBZDXQGFVPTXDZ-UHFFFAOYSA-N 0.000 claims 1
- UHISQLHPYWNPQW-UHFFFAOYSA-N n-ethyl-3-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]propan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCCNCC)=CC=CC2=C1 UHISQLHPYWNPQW-UHFFFAOYSA-N 0.000 claims 1
- ABFPREJKBODYNG-UHFFFAOYSA-N n-ethyl-4-(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)butan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)CCCCNCC)=CC=CC2=C1 ABFPREJKBODYNG-UHFFFAOYSA-N 0.000 claims 1
- IHLKUQBGQVWNRH-UHFFFAOYSA-N n-ethyl-4-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]butan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCCCNCC)=CC=CC2=C1 IHLKUQBGQVWNRH-UHFFFAOYSA-N 0.000 claims 1
- BMTZTTRCLUSICH-UHFFFAOYSA-N n-ethyl-n-methyl-2-(1-methyl-3-naphthalen-1-ylsulfonylindazol-5-yl)oxyethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NN(C)C4=CC=C(C=C43)OCCN(C)CC)=CC=CC2=C1 BMTZTTRCLUSICH-UHFFFAOYSA-N 0.000 claims 1
- IWDPUZMWDBQBAA-UHFFFAOYSA-N n-ethyl-n-methyl-2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCN(C)CC)=CC=CC2=C1 IWDPUZMWDBQBAA-UHFFFAOYSA-N 0.000 claims 1
- IPFIGNDGZJQBJY-UHFFFAOYSA-N n-ethyl-n-methyl-3-(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)propan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)CCCN(C)CC)=CC=CC2=C1 IPFIGNDGZJQBJY-UHFFFAOYSA-N 0.000 claims 1
- KFBPBGMNYWGBTK-UHFFFAOYSA-N n-ethyl-n-methyl-3-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]propan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCCN(C)CC)=CC=CC2=C1 KFBPBGMNYWGBTK-UHFFFAOYSA-N 0.000 claims 1
- DEHPBFBLXYBYKG-UHFFFAOYSA-N n-ethyl-n-methyl-4-(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)butan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)CCCCN(C)CC)=CC=CC2=C1 DEHPBFBLXYBYKG-UHFFFAOYSA-N 0.000 claims 1
- NCTFDQWFOOHFFC-UHFFFAOYSA-N n-methyl-2-(1-methyl-3-naphthalen-1-ylsulfonylindazol-5-yl)oxyethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NN(C)C4=CC=C(C=C43)OCCNC)=CC=CC2=C1 NCTFDQWFOOHFFC-UHFFFAOYSA-N 0.000 claims 1
- BQHVXLWCYFWZGS-UHFFFAOYSA-N n-methyl-2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCNC)=CC=CC2=C1 BQHVXLWCYFWZGS-UHFFFAOYSA-N 0.000 claims 1
- JBMWZPXTNHKTRF-UHFFFAOYSA-N n-methyl-2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-6-yl)oxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C4=CC=C(C=C4NN=3)OCCNC)=CC=CC2=C1 JBMWZPXTNHKTRF-UHFFFAOYSA-N 0.000 claims 1
- SXSSVYDHGMXGJG-UHFFFAOYSA-N n-methyl-2-[(3-naphthalen-1-ylsulfonyl-2h-indazol-7-yl)oxy]ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C=4C=CC=C(C=4NN=3)OCCNC)=CC=CC2=C1 SXSSVYDHGMXGJG-UHFFFAOYSA-N 0.000 claims 1
- UQBWGYCLUQQNGZ-UHFFFAOYSA-N n-methyl-3-(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)propan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)CCCNC)=CC=CC2=C1 UQBWGYCLUQQNGZ-UHFFFAOYSA-N 0.000 claims 1
- XJBFZLJZSPJQRV-UHFFFAOYSA-N n-methyl-3-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]propan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCCNC)=CC=CC2=C1 XJBFZLJZSPJQRV-UHFFFAOYSA-N 0.000 claims 1
- CBLRBCBDAPHUDF-UHFFFAOYSA-N n-methyl-3-[(3-naphthalen-1-ylsulfonyl-2h-indazol-7-yl)oxy]propan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C=3C=4C=CC=C(C=4NN=3)OCCCNC)=CC=CC2=C1 CBLRBCBDAPHUDF-UHFFFAOYSA-N 0.000 claims 1
- BASVWLXZWDUZQN-UHFFFAOYSA-N n-methyl-4-[(3-naphthalen-1-ylsulfonyl-2h-indazol-5-yl)oxy]-n-propylbutan-1-amine Chemical compound C1=CC=C2C(S(=O)(=O)C3=NNC4=CC=C(C=C43)OCCCCN(C)CCC)=CC=CC2=C1 BASVWLXZWDUZQN-UHFFFAOYSA-N 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70831505P | 2005-08-15 | 2005-08-15 | |
| US60/708,315 | 2005-08-15 | ||
| PCT/US2006/030965 WO2007021711A2 (en) | 2005-08-15 | 2006-08-08 | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009504739A JP2009504739A (ja) | 2009-02-05 |
| JP2009504739A5 true JP2009504739A5 (enExample) | 2009-09-24 |
| JP5146766B2 JP5146766B2 (ja) | 2013-02-20 |
Family
ID=37668440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008526995A Expired - Fee Related JP5146766B2 (ja) | 2005-08-15 | 2006-08-08 | ５−ヒドロキシトリプタミン−６リガンドとしての置換−３−スルホニルインダゾール誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7723329B2 (enExample) |
| EP (1) | EP1931640A2 (enExample) |
| JP (1) | JP5146766B2 (enExample) |
| KR (1) | KR20080039994A (enExample) |
| CN (1) | CN101282938A (enExample) |
| AR (1) | AR057756A1 (enExample) |
| AU (1) | AU2006280091A1 (enExample) |
| BR (1) | BRPI0614343A2 (enExample) |
| CA (1) | CA2619010C (enExample) |
| CR (1) | CR9734A (enExample) |
| EC (1) | ECSP088189A (enExample) |
| GT (1) | GT200600376A (enExample) |
| IL (1) | IL189476A0 (enExample) |
| NO (1) | NO20080937L (enExample) |
| NZ (1) | NZ565872A (enExample) |
| PE (1) | PE20070354A1 (enExample) |
| RU (1) | RU2429231C2 (enExample) |
| SA (1) | SA06270314B1 (enExample) |
| TW (1) | TW200740766A (enExample) |
| UA (1) | UA94053C2 (enExample) |
| WO (1) | WO2007021711A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080114688A (ko) * | 2006-01-13 | 2008-12-31 | 와이어쓰 | 5-히드록시트립타민 수용체에 대한 리간드로서의 술포닐 치환된 1ｈ-인돌 |
| PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| CA2647141A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands |
| WO2007120599A2 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands |
| WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
| US20090012308A1 (en) * | 2007-06-13 | 2009-01-08 | Wyeth | Process for the manufacture of benzylsulfonylarenes |
| CN103102322B (zh) * | 2011-11-14 | 2016-02-24 | 上海交通大学 | 噁唑类化合物及其制备方法、药物组合物及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001521926A (ja) | 1997-11-04 | 2001-11-13 | ファイザー・プロダクツ・インク | 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換 |
| EP1196380A2 (en) | 1999-07-15 | 2002-04-17 | NPS Allelix Corp. | Indoles and indazoles for the treatment of migraine |
| WO2002036562A2 (en) * | 2000-11-02 | 2002-05-10 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| KR20030062442A (ko) | 2000-12-22 | 2003-07-25 | 와이어쓰 | 5-하이드록시트립타민-6-리간드로서의 헤테로사이클인다졸및 아자인다졸 화합물 |
| DK1355900T3 (da) | 2000-12-22 | 2006-09-11 | Wyeth Corp | Heterocyclylalkylindol- eller -azaindolforbindelser som 5-hydroxytryptamin-6-ligander |
| TW593278B (en) | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| KR20030088508A (ko) | 2001-04-20 | 2003-11-19 | 와이어쓰 | 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴옥시-, -티옥시- 및 -아미노벤즈아졸 유도체 |
| CN1293073C (zh) | 2001-04-20 | 2007-01-03 | 惠氏公司 | 作为5－羟色胺－6配体的杂环基烷氧基－、－烷硫基－和－烷基氨基吲哚衍生物 |
| PL367305A1 (en) * | 2001-06-07 | 2005-02-21 | F.Hoffmann-La Roche Ag | New indole derivatives with 5-ht6 receptor affinity |
| EP1403255A4 (en) | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | RHO KINASE INHIBITORS |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| TW200400177A (en) * | 2002-06-04 | 2004-01-01 | Wyeth Corp | 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| US7943639B2 (en) | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
| TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| TW200403243A (en) | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| RU2324693C2 (ru) * | 2002-10-18 | 2008-05-20 | Ф.Хоффманн-Ля Рош Аг | 4-пиперазинилбензолсульфонилиндолы, характеризующиеся сродством к рецептору 5-нт6 |
| CA2508315A1 (en) * | 2002-12-03 | 2004-06-17 | F. Hoffmann-La Roche Ag | Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders |
| EP1592683A2 (en) | 2003-02-14 | 2005-11-09 | Wyeth | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
| TW200418830A (en) * | 2003-02-14 | 2004-10-01 | Wyeth Corp | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| BRPI0508107A (pt) | 2004-02-27 | 2007-07-17 | Hoffmann La Roche | derivados de indazol e composições farmacêuticas contendo os mesmos |
| KR20080034497A (ko) | 2005-08-15 | 2008-04-21 | 와이어쓰 | 5-히드록시트립타민-6 리간드로서의 아지닐-3-설포닐인다졸유도체 |
-
2006
- 2006-08-08 BR BRPI0614343-1A patent/BRPI0614343A2/pt not_active IP Right Cessation
- 2006-08-08 CA CA2619010A patent/CA2619010C/en not_active Expired - Fee Related
- 2006-08-08 UA UAA200801842A patent/UA94053C2/ru unknown
- 2006-08-08 JP JP2008526995A patent/JP5146766B2/ja not_active Expired - Fee Related
- 2006-08-08 AU AU2006280091A patent/AU2006280091A1/en not_active Abandoned
- 2006-08-08 EP EP06801007A patent/EP1931640A2/en not_active Withdrawn
- 2006-08-08 CN CNA2006800374446A patent/CN101282938A/zh active Pending
- 2006-08-08 WO PCT/US2006/030965 patent/WO2007021711A2/en not_active Ceased
- 2006-08-08 RU RU2008105807/04A patent/RU2429231C2/ru not_active IP Right Cessation
- 2006-08-08 KR KR1020087006267A patent/KR20080039994A/ko not_active Ceased
- 2006-08-08 NZ NZ565872A patent/NZ565872A/en unknown
- 2006-08-14 US US11/504,350 patent/US7723329B2/en not_active Expired - Fee Related
- 2006-08-14 PE PE2006000984A patent/PE20070354A1/es not_active Application Discontinuation
- 2006-08-14 GT GT200600376A patent/GT200600376A/es unknown
- 2006-08-14 TW TW095129795A patent/TW200740766A/zh unknown
- 2006-08-14 AR ARP060103549A patent/AR057756A1/es unknown
- 2006-09-09 SA SA6270314A patent/SA06270314B1/ar unknown
-
2008
- 2008-02-12 IL IL189476A patent/IL189476A0/en unknown
- 2008-02-15 CR CR9734A patent/CR9734A/es not_active Application Discontinuation
- 2008-02-15 EC EC2008008189A patent/ECSP088189A/es unknown
- 2008-02-25 NO NO20080937A patent/NO20080937L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103497188B (zh) | 调节c‑fms和/或c‑kit活性的化合物及其应用 | |
| RU2386630C2 (ru) | Соединения и композиции в качестве ингибиторов протеинтирозинкиназы | |
| RU2406725C2 (ru) | Соединения и композиции как ингибиторы протеинкиназы | |
| DK2889298T3 (en) | 4-POSITION-SUBSTITUTED PYRAZOLOPYRIMIDINE DERIVATE AND ITS USE IN PHARMACEUTICAL PREPARATION | |
| JP2020183410A5 (enExample) | ||
| JP2009538910A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| JP2014139226A5 (enExample) | ||
| RU2012134306A (ru) | Азотосодержащие производные гетероарилов | |
| CN1639153A (zh) | 吲哚基马来酰亚胺衍生物 | |
| JP2015531773A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2017510555A5 (enExample) | ||
| AU2018360850A1 (en) | Modulators of the integrated stress pathway | |
| JP2009541461A5 (enExample) | ||
| PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
| RS55863B1 (sr) | Inhibitori kinaze pirazolil hinoksalina | |
| JP2013510876A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| JP2006510716A5 (enExample) | ||
| JP2007519695A5 (enExample) | ||
| JP2015500862A5 (enExample) | ||
| WO2015056683A1 (ja) | 含窒素複素環化合物の塩またはその結晶、医薬組成物およびｆｌｔ３阻害剤 | |
| CN102177136A (zh) | 吡咯烷n-苄基衍生物 | |
| JPWO2021170109A5 (enExample) | ||
| JP2019014762A (ja) | ニロチニブ塩酸塩の多形形態 |